Menu Search
Equities

Royalty Pharma PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
RPD:MUN

Royalty Pharma PLC

Actions
  • Price (EUR)37.71
  • Today's Change0.29 / 0.77%
  • Shares traded40.00
  • 1 Year change+21.45%
  • Beta0.3970
Data delayed at least 15 minutes, as of Feb 16 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Royalty Pharma PLC had net income fall -10.25% from 858.98m to 770.95m despite a 5.06% increase in revenues from 2.26bn to 2.38bn. An increase in the selling, general and administrative costs as a percentage of sales from 10.46% to 27.86% was a component in the falling net income despite rising revenues.
Gross margin--
Net profit margin55.68%
Operating margin65.58%
Return on assets7.00%
Return on equity11.49%
Return on investment9.03%
More ▼

Cash flow in USDView more

In 2025, cash reserves at Royalty Pharma PLC fell by 310.33m. However, the company earned 2.49bn from its operations for a Cash Flow Margin of 104.69%. In addition the company used 1.61bn on investing activities and also paid 1.19bn in financing cash flows.
Cash flow per share1.59
Price/Cash flow per share29.14
Book value per share11.22
Tangible book value per share9.62
More ▼

Balance sheet in USDView more

Royalty Pharma PLC has a Debt to Total Capital ratio of 47.95%, a lower figure than the previous year's 95.22%.
Current ratio2.40
Quick ratio--
Total debt/total equity1.38
Total debt/total capital0.4795
More ▼

Growth rates in USD

SmartText is unavailable
Div yield(5 year avg)2.31%
Div growth rate (5 year)24.01%
Payout ratio (TTM)49.07%
EPS growth(5 years)6.20
EPS (TTM) vs
TTM 1 year ago		-7.15
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.